|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00635414 |
This study looks at the effect on basal and pentagastrin-stimulated acid output of 40 mg Esomeprazole (Nexium) administered orally and intravenously as a 15-minute infusion to people with symptoms of Gastroesophageal Reflux Disease (GERD)
Condition | Intervention | Phase |
GERD |
Drug: Esomeprazole |
Phase III |
MedlinePlus related topics: | GERD |
ChemIDplus related topics: | Esomeprazole magnesium Esomeprazole Sodium Omeprazole Omeprazole magnesium Pentagastrin |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Crossover Assignment, Safety/Efficacy Study |
Official Title: | An Open, Randomized, Two-Way Crossover Study Comparing the Effect of 40mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD). |
Estimated Enrollment: | 60 |
Study Start Date: | August 2002 |
Study Completion Date: | December 2002 |
Primary Completion Date: | October 2002 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Experimental
40mg administered orally
|
Drug: Esomeprazole
40mg oral
|
2: Experimental
15 minute intravenous infusion
|
Drug: Esomeprazole
15 minute intravenous infusion
|
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | SH-NEP-0011, D9615C00011 |
First Received: | March 6, 2008 |
Last Updated: | March 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00635414 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|